Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines has a positive growth outlook primarily driven by the anticipated revenue increase from the upcoming launches of zanidatamab and tarlatamab in China, in addition to ongoing revenue growth from established products like Xgeva and Kyprolis. The company’s core drug, Brukinsa, along with promising clinical outcomes in lymphoma, where response rates are around 50%, is expected to contribute significantly to revenues, potentially adding approximately $650 million by 2034. Furthermore, BeOne's innovative strategies with next-generation approaches, such as sonro and ‘673, are positioned to support continued topline growth despite potential pricing pressures in the market.

Bears say

BeOne Medicines faces a negative outlook primarily due to the slower than expected uptake of its commercial products, particularly the core drug Brukinsa, which accounts for over 60% of the company's revenue. Additionally, the company's pipeline suffers from potential failures in expanding indications, including the unsuccessful solid tumor initiative and drug candidates such as sonrotoclax and '673, which further jeopardize future growth. Compounding these challenges, historical revenue misses in the second half of previous years raise concerns regarding the sustainability and reliability of Brukinsa's sales going forward.

BeiGene Ltd (ONC) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 8 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $353, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $353, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.